Search | IOVS | ARVO Journals

Showing 1 – 20 of 79

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Sustained release of Sh3-RdCVF improves cone function and survival in rd1 mice

Lia Huo; Carter Teal; Daniela Isaacs; Margaret T. Ho; Thierry Leveillard; Shira Albeck; Tamar Unger; Robert Fluhr; Valerie A. Wallace; Molly S. Shoichet

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4930.

ARVO Annual Meeting Abstract June 2024

Both NXNL1 and NXNL2 are important for photoreceptor survival in the mouse

Zheng LI; Imen Harichane; Ying Yang; Emmanuelle Clerin; Jose Alain Sahel; Isabelle S Audo; Christina Zeitz; Thierry Leveillard

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4771.

ARVO Annual Meeting Abstract June 2023

Nonclinical safety and pharmacokinetic assessment of SPVN06, an AAV-based gene therapy for the treatment of rod-cone dystrophies.

Anne-Sophie Gautron; Melanie Marie; Lucie Churet; Hanen Khabou; Gregg Prawdzik; Thierry Léveillard; José-Alain Sahel; Florence Lorget

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):773.

ARVO Annual Meeting Abstract June 2023

Sustained Release of Sh3-RdCVF to Rescue Cone Photoreceptor Death

Lia Huo; Carter Teal; Daniela Isaacs; Margaret Ho; Thierry Léveillard; Shira Albeck; Tamar Unger; Robert Fluhr; Molly Shoichet

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2621.

ARVO Annual Meeting Abstract June 2023

Mouse model selection for pharmacological evaluation of AAV-based therapeutic agents for the treatment of Rod-Cone Dystrophies (RCD)

Melanie MARIE; Lucie Churet; Hanen Khabou; Daniel C Chung; Jose Sahel; Thierry Léveillard; Florence Lorget

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2591.

ARVO Annual Meeting Abstract June 2023

Characterization of a mouse model of metabolism in age-related macular degeneration, the Slc16a8 MAD/MAD mouse

Emmanuelle Clerin; Léa Thiébault; John Yeong Se Han; Imen Harichane; Laurence Klipfel; Sébastien Augustin; Cécile Delarasse; Florian Sennlaub; Nancy Philp; Thierry Léveillard

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):5386.

ARVO Annual Meeting Abstract June 2022

SPVN06, a novel mutation-independent AAV-based gene therapy, dramatically reduces vision loss in the rd10 mouse model of rod-cone dystrophy

Florence Lorget; Melanie Marie; Hanen Khabou; Cardillia Simon; Didier Nuno; Phillip Vanlandingham; Alain Quiambao; Rafal Farjo; Deniz Dalkara; Jose Alain Sahel; Thierry D Leveillard

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):56 – A0029.

ARVO Annual Meeting Abstract June 2022

The potential role of rod-derived cone viability factor long (RdCVFL) in treating retinitis pigmentosa as a thioredoxin-like protein

Xiaoyuan Ren; Arne Holmgren; Elias S.J. Arnér; Thierry D Leveillard

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3900 – A0102.

ARVO Annual Meeting Abstract June 2022

Metabolic defects and circadian clock alterations in Prpf31 -mutant mice.

Elora Vanoni; Abdallah Hamieh; Géraldine Puel; Thierry D Leveillard; Emeline F Nandrot

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3819.

ARVO Annual Meeting Abstract June 2022

Retrospective natural history of retinitis pigmentosa due to RHO , PDE6A, or PDE6B mutations: the PHENOROD1 study

Alice Le Meur; Daniel C Chung; Léa Thiebault; Pierre-Axel Vinot; Berthe Pom; Thierry D Leveillard; Saddek Mohand-Said; Jose Alain Sahel; Isabelle S Audo

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):4497 – F0284.

ARVO Annual Meeting Abstract June 2021

A 1-Month Toxicology and Biodistribution NHP Pilot Study Evaluating a Single Subretinal Bilateral Administration of SPVN06 - A Novel AAV-Based Gene Therapy for the Treatment of Rod-Cone Dystrophies Agnostic of the Causative Mutation

Melanie MARIE; Myriam Marussig; Pierre-Axel VINOT; Thomas VIHTELIC; Ryan F. Boyd; Lauren KNUPP; Jennifer LAMOUREUX; Thierry D Leveillard; Jose Alain Sahel; Florence LORGET

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):194.

ARVO Annual Meeting Abstract June 2021

SPVN06, a Novel Mutation-Independent AAV-based Gene Therapy, Protects Cone Degeneration in a Pig Model of Retinitis Pigmentosa

Jennifer Noel; archana jalligampala; Myriam Marussig; Pierre-Axel VINOT; Melanie MARIE; Melanie Butler; Florence LORGET; Stephane Boissel; Thierry D Leveillard; Jose Alain Sahel; Maureen A McCall

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1189.

ARVO Annual Meeting Abstract June 2021

A mouse model with specific inactivation of the thioredoxin-like protein encoded by the nucleoredoxin-like1 reveals its role in the prevention of secondary cone death in retinitis pigmentosa

Emmanuelle Clerin; Emanuele Procopio; Stephanie M Hauck; Jose-Alain Sahel; Erika Tatiana Camacho; Thierry D Leveillard

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):2256.

ARVO Annual Meeting Abstract June 2021

Correlations between progression markers in rod-cone dystrophy due to mutations in RHO, PDE6A, or PDE6B .

Daniel C Chung; Pierre-Axel VINOT; Myriam Marussig; Léa Thiébault; Berthe Pom; Camille Andrieu; Christina Zeitz; Thierry D Leveillard; Stephane Boissel; Saddek Mohand-Said; Isabelle Audo; Jose-Alain Sahel

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):3539.

ARVO Annual Meeting Abstract June 2020

Natural history of retinitis pigmentosa due to RHO , PDE6A OR PDE6B mutations

Myriam Marussig; Léa Thiebault; Pierre-Axel Vinot; Berthe Pom; Camille Andrieu; Christina Zeitz; Thierry D Leveillard; Florence Allouche; Saddek Mohand-Said; Isabelle S Audo; Jose Alain Sahel

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3035.

ARVO Annual Meeting Abstract July 2019

Modeling Cone Aerobic Glycolysis

Erika Tatiana Camacho; Danielle Brager; Ghizlane Elachouri; Tatyana Korneyeva; Geraldine Millet-Puel; Jose Alain Sahel; Thierry D Leveillard

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):567.

ARVO Annual Meeting Abstract July 2019

Mathematically Assessing the Contributions of Key Processes in Cone Aerobic Glycolysis

Danielle Brager; Erika Tatiana Camacho; Ghizlane Elachouri; Tatyana Korneyeva; Geraldine Millet-Puel; Jose Alain Sahel; Thierry D Leveillard

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):569.

ARVO Annual Meeting Abstract July 2019

Mutations in WDR34 is a rare cause of non-syndromic autosomal recessive rod-cone dystrophy

Isabelle S Audo; Maria Solaguren-Beascoa; Kinga Bujakowska; Cécile Méjécase; Lisa Emmengger; Saddek Mohand-Said; Thierry D Leveillard; Eric A Pierce; Helene Dollfus; Jose Alain Sahel; Shomi Bhattacharya; Christina Zeitz

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):381.

ARVO Annual Meeting Abstract July 2019

A CCDC51 frameshift variant as a candidate gene defect for autosomal recessive rod-cone dystrophy

Christina Zeitz; Cécile Méjécase; Saddek Mohand-Saïd; Lisa Emmengger; Audrey Schalk; Marion Neuillé; Elise Orhan; Frédéric Blond; Camille Prévot; Sandra Sandra Chantot-Bastaraud; Thierry D Leveillard; Jose Alain Sahel; Isabelle S Audo

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):415.

ARVO Annual Meeting Abstract July 2019

6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 governs the metabolic flux between rod and cone photoreceptors

Géraldine Millet Puel; Marie Cordonnier; Alexandra Saint-charles; Emmanuelle Clerin; Frédéric Blond; Seiki Achiedo; Najate Ait-Ali; Orna Corchia; Laurence Klipfel; Ying Yang; Raju V S Rajala; Erika Tatiana Camacho; Thierry D Leveillard

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):6404.

1 2 3 4

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Sustained release of Sh3-RdCVF improves cone function and survival in rd1 mice

Both NXNL1 and NXNL2 are important for photoreceptor survival in the mouse

Nonclinical safety and pharmacokinetic assessment of SPVN06, an AAV-based gene therapy for the treatment of rod-cone dystrophies.

Sustained Release of Sh3-RdCVF to Rescue Cone Photoreceptor Death

Mouse model selection for pharmacological evaluation of AAV-based therapeutic agents for the treatment of Rod-Cone Dystrophies (RCD)

Characterization of a mouse model of metabolism in age-related macular degeneration, the Slc16a8 MAD/MAD mouse

SPVN06, a novel mutation-independent AAV-based gene therapy, dramatically reduces vision loss in the rd10 mouse model of rod-cone dystrophy

The potential role of rod-derived cone viability factor long (RdCVFL) in treating retinitis pigmentosa as a thioredoxin-like protein

Metabolic defects and circadian clock alterations in Prpf31 -mutant mice.

Retrospective natural history of retinitis pigmentosa due to RHO , PDE6A, or PDE6B mutations: the PHENOROD1 study

A 1-Month Toxicology and Biodistribution NHP Pilot Study Evaluating a Single Subretinal Bilateral Administration of SPVN06 - A Novel AAV-Based Gene Therapy for the Treatment of Rod-Cone Dystrophies Agnostic of the Causative Mutation

SPVN06, a Novel Mutation-Independent AAV-based Gene Therapy, Protects Cone Degeneration in a Pig Model of Retinitis Pigmentosa

A mouse model with specific inactivation of the thioredoxin-like protein encoded by the nucleoredoxin-like1 reveals its role in the prevention of secondary cone death in retinitis pigmentosa

Correlations between progression markers in rod-cone dystrophy due to mutations in RHO, PDE6A, or PDE6B .

Natural history of retinitis pigmentosa due to RHO , PDE6A OR PDE6B mutations

Modeling Cone Aerobic Glycolysis

Mathematically Assessing the Contributions of Key Processes in Cone Aerobic Glycolysis

Mutations in WDR34 is a rare cause of non-syndromic autosomal recessive rod-cone dystrophy

A CCDC51 frameshift variant as a candidate gene defect for autosomal recessive rod-cone dystrophy

6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 governs the metabolic flux between rod and cone photoreceptors

To View More...

You must be signed into an individual account to use this feature.